ICT-107
ImmunoCellular awarded $19.9 million grant for ICT-107 phase 3 trial for glioblastoma
September 25, 2015Research and Development California Institute for Regenerative Medicine, Cancer, ICT-107, brain cancer, glioblastoma
ImmunoCellular Therapeutics has been awarded a $19.9 million grant by California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
